Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 1 FXIIa-serpin complexes and aCL antibodies in association with VD in SLE patients

From: Contact activation products are new potential biomarkers to evaluate the risk of thrombotic events in systemic lupus erythematosus

  VD-, n (%) VD+, n (%) P-value a OR (95% CI)
All 38 (55) 31 (45)   
FXIIa-C1INH <0.01 nMb 14 (37) 24 (77) P <0.0001 8.9 (2.8, 28.5)
FXIIa-AT >0.40 nMc 4 (11) 13 (42) P = 0.0043 6.1 (1.7, 21.6)
Both low FXIIa-C1INH 1 (3) 12 (39) P <0.0001 23.4 (2.8, 194)
and high FXIIa-AT
aCL antibodies 12 (32) 15 (48) n.s. 2.0 (0.8, 5.4)
  1. SLE, systemic lupus erythematosus; VD, vascular disease; F, factor; C1INH, C1 inhibitor; AT, antithrombin; Acl, anti-cardiolipin; OR, odds ratio; n.s., not significant. aFisher's exact test; b0.01 nM = detection limit of the assay; c0.40 nM = 90% percentile of controls.